N,N-二甲基-2-溴苯磺酰胺 | 65000-13-7

• 物质功能分类: 原料药 - 人工合成抗感染类药 - 磺胺类药及增效剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N,N-二甲基-2-溴苯磺酰胺
• 中文别名: 2-溴-N,N-二甲基苯磺胺
• 英文名称: 2-bromo-N,N-dimethylbenzenesulfonamide
• CAS: 65000-13-7
• 化学式: C₈H₁₀BrNO₂S
• mdl: MFCD07368229
• 分子量: 264.143
• InChiKey: OGYMDBJRCOBHEY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2935009090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N,N-Dimethyl 2-bromobenzenesulfonamide
Synonyms: 2-Bromo-N,N-dimethylbenzenesulfonamide

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: N,N-Dimethyl 2-bromobenzenesulfonamide
CAS number: 65000-13-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H10BrNO2S
Molecular weight: 264.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N,N-二甲基-2-溴苯磺酰胺 在 palladium diacetate 、 caesium carbonate 、 tricyclohexylphosphine tetrafluoroborate 、 三甲基乙酸 作用下， 以 均三甲苯 为溶剂， 反应 16.0h， 以56%的产率得到2-methyl-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide
  参考文献：
  名称：

  Pd(0)催化分子内烷烃芳基化与酰胺和磺酰胺相邻的C(sp3)-H键断裂机理研究

  摘要：

  可以调整与氮原子相邻的 C(sp(3))-H 键的反应性，以允许在 Pd(0) 催化下进行分子内烷烃芳基化。降低氮孤对的路易斯碱度对于这种催化活性至关重要。一系列 N-甲基酰胺和磺酰胺仅在初级 C(sp(3))-H 键上反应，以高产率提供烷烃芳基化产物。Pd(II) 反应中间体的分离使得能够评估反应机理，重点是碱在 C(sp(3))-H 键断裂步骤中的作用。这些化学计量研究的结果，连同动力学同位素效应实验，为协调的金属化-去质子化 (CMD) 过渡态提供了罕见的实验支持，此前已在烷烃 C(sp(3))-H 芳基化中提出了这种过渡态。而且，DFT 计算揭示了新戊酸盐添加剂作为磷化氢从 Pd(II) 中间体解离的促进剂的额外作用，使 CMD 过渡态成为可能。最后，进行了动力学研究，揭示了反应速率表达及其与新戊酸盐浓度的关系。

  DOI：

  10.1021/ja103081n
• 作为产物：
  描述：

  2-溴苯磺酰氯 在 一水合肼 、 sodium sulfate 作用下， 以 四氢呋喃 、 水 、 乙腈 为溶剂， 反应 9.25h， 生成 N,N-二甲基-2-溴苯磺酰胺
  参考文献：
  名称：

  到C-N活化的方法：芳烃磺酰基酰肼和芳烃磺酰基氯化物与耦合叔-胺通过一个金属，氧化剂-和不含卤素的阳极氧化

  摘要：

  叔-胺套着，得到芳烃磺酰基酰肼和芳烃磺酰基氯化物经由一个金属，氧化剂-和不含卤素的电化学氧化偶合中在RT未分割细胞。这种环境友好的方法使用廉价且可再生的铅笔状石墨电极（PGE），以令人满意的产率提供了范围广泛的磺酰胺。

  DOI：

  10.1039/c7gc03141f

文献信息

• Synthesis and Reactivity of ¹⁸F-Labeled α,α-Difluoro-α-(aryloxy)acetic Acids
  作者：Tanatorn Khotavivattana、Samuel Calderwood、Stefan Verhoog、Lukas Pfeifer、Sean Preshlock、Neil Vasdev、Thomas L. Collier、Véronique Gouverneur

  DOI：10.1021/acs.orglett.6b03730

  日期：2017.2.3

  In this work, we describe the 18F-labeling of α,α-difluoro-α-(aryloxy)acetic acid derivatives and demonstrate that these building blocks are amenable to post-18F-fluorination functionalization. Protodecarboxylation offers a new entry to 18F-difluoromethoxyarene, and the value of this approach is further demonstrated with coupling processes leading to representative 18F-labeled TRPV1 inhibitors and

  在这项工作中，我们描述了α，α-二氟-α-（芳氧基）乙酸衍生物的18 F标记，并证明这些构件适用于18 F后氟化功能化。原羧化为18 F-二氟甲氧基芳烃提供了新的进入途径，并且该方法的价值通过偶联过程得到了进一步证明，该偶联过程导致了代表性的18 F标记的TRPV1抑制剂和TRPV1拮抗剂。
• [EN] INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME<br/>[FR] INHIBITEURS DE L'ARN POLYMERASE ARN-DEPENDANTE DU VIRUS DE L'HEPATITE C ET COMPOSITIONS ET TRAITEMENTS UTILISANT CETTE POLYMERASE
  申请人：PFIZER

  公开号：WO2003095441A1

  公开（公告）日：2003-11-20

  Compounds of formula (I) are hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp) inhibitors, and are useful in therapeutic and prophylactic treatment of persons infected with hepatitis C virus.

  化合物的化学式（I）是丙型肝炎病毒（HCV）RNA依赖性RNA聚合酶（RdRp）抑制剂，对感染丙型肝炎病毒的人进行治疗和预防性治疗具有用处。
• A Method for Identifying and Developing Functional Group Tolerant Catalytic Reactions: Application to the Buchwald–Hartwig Amination
  作者：Jeffery Richardson、J. Craig Ruble、Elizabeth A. Love、Simon Berritt

  DOI：10.1021/acs.joc.7b00201

  日期：2017.4.7

  individual functional groups on the success of a transformation under various conditions and provides a simple framework for identifying new conditions that tolerate challenging functional groups. Application of this approach to profile the conditions for the Buchwald–Hartwig amination and rapidly identify bespoke conditions for challenging substrate classes is described.

  过渡金属催化彻底改变了有机合成方法，但是将其应用于高度功能化的分子（如药物及其前体）时，通常会遇到困难。这导致发现集合中富集了具有不太理想的特性（高亲脂性，低极性表面积）的物质。经常使用掩蔽基团来解决这个问题，这与这些方法对于绿色化学和原子经济的内在理想相反。Glorius等人描述的与健壮性筛选有关的通用筛选方法，可以广泛理解各个官能团对各种条件下转化成功的影响，并提供一个简单的框架来鉴定可耐受具有挑战性的官能团的新条件。
• [EN] PYRROLIDINE-2-ONES AS FACTOR XA INHIBITORS<br/>[FR] PYRROLIDINE-2-ONES UTILISEES COMME INHIBITEURS DU FACTEUR XA
  申请人：GLAXO GROUP LTD

  公开号：WO2003053925A1

  公开（公告）日：2003-07-03

  The invention relates to compounds of formula (I): , and pharmaceutically acceptable derivatives thereof. The invention also relates to processes for the preparation of compounds of formula (I), pharmaceutical compositions containing compounds of formula (I) and to the use of compounds of formula (I) in medicine, particularly in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.

  该发明涉及式（I）的化合物，以及其药学上可接受的衍生物。该发明还涉及制备式（I）化合物的方法，含有式（I）化合物的药物组合物以及在医学上使用式（I）化合物，特别是在改善需要使用FXa抑制剂的临床病情方面的用途。
• Arylamines for the treatment of conditions associated with gsk-3
  申请人：Berg Stefan

  公开号：US20060052396A1

  公开（公告）日：2006-03-09

  The present invention relates to new compounds of formula (I) wherein Z, Y, X, P, Q, R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , A, m and n are defined as in any one of claims 1 to 3, a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds for the treatment of conditions associated with glycogens synthase kinase-3 (GSK3).

  本发明涉及具有公式（I）的新化合物，其中Z、Y、X、P、Q、R、R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、A、m和n的定义如权利要求1至3中的任意一项，以及制备它们的过程和其中制备的新中间体，含有所述治疗活性化合物的制药配方以及使用所述活性化合物治疗与糖原合酶激酶-3（GSK3）相关的疾病的方法。